ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2573

Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling

Uta Kiltz1, Mickaël Hiligsmann2, D van der Heijde3, Juergen Braun1, Alarcos Cieza4, Walter P. Maksymowych5, William Taylor6 and Annelies Boonen7, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium, 3Leiden University Medical Center, Leiden, Netherlands, 4Department of Psychology, University Southampton, Southampton, United Kingdom, 5University of Alberta, Edmonton, AB, Canada, 6Department of Medicine, University of Otago Wellington, Wellington, New Zealand, 7Maastricht University Medical Center, Maastricht, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose

The ASAS Health Index (ASAS HI) is a disease-specific questionnaire aiming at measurement of health in patients with spondyloarthritis (SpA) which has been developed by Assessment of SpondyloArthritis international Society (ASAS). The 17 items of the ASAS HI address aspects of pain, emotional functions, sleep, sexual functions, mobility, self-care and community life based on the International Classification of Functioning, Disability and Health (ICF). These items can serve as the starting point to develop a disease-specific utility instrument that will enable to calculate disease specific quality adjusted life-years. To construct such utility instrument, the development steps require that the number of items should be reduced to a more manageable number of items. This selection should be based on items, which are most essential to patient’s health and on items which are most preferred by patients. It is not know which aspects of health matter most to patients with SpA and also the knowledge about patient’s preferences is limited. The objective is to understand the relative importance of the different items of the ASAS HI for functioning and health of patients with SpA.

Methods

A best-worse experiment was conducted using a questionnaire in patients with SpA from 20 countries worldwide. Patients answered 17 choice tasks that were constructed using the Sawtooth software. In each task, patients were asked to choose the most important item and the least important from a set of four items about their functioning and health.. The estimated hierarchical Bayes method was used to generate the mean relative importance score for each item.

Results 206 patients (59.7% male, mean (SD) age 42.4 (13.9) years, mean (SD) BASDAI 3.8 (2.3)) with SpA completed the experiment. The five most important items are pain, sleep, standing, exhausting, and motivation to do anything that requires physical effort (figure 1). Eight items addresses concepts which are less important for the patients: toileting, sexual relations, driving, contact with people, walking outdoors, concentration, washing hair, and be able to overcome difficulties. Four items addresses concepts, which showed intermediate results addressing concepts of running, frustration, traveling, and financial changes. Subgroup analysis regarding subgroups of SpA and European versus Non-European countries showed robust results among subgroups.

Conclusion

This study provides information on the relative importance for patients with spondyloarthritis of the items of the ASAS Health Index that will be used for the development of a utility-based instrument.


Disclosure:

U. Kiltz,
None;

M. Hiligsmann,
None;

D. van der Heijde,

AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex,

5;

J. Braun,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

9,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

9,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

5,

Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB,

2;

A. Cieza,
None;

W. P. Maksymowych,

AbbVie,

5,

AbbVie,

2,

AbbVie,

8;

W. Taylor,

Pfizer Inc,

5,

Metabolex,

5,

Abbvie,

9;

A. Boonen,

Amgen, AbbVie, Merck and Pfizer,

2,

UCB and Pfizer,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preferences-of-patients-with-spondyloarthritis-for-the-items-of-the-asas-health-index-a-best-worst-scaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology